HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jaakko Puttonen Selected Research

N- (4- (4- methyl- 6- oxo- 1,4,5,6- tetrahydropyridazin- 3- yl)phenyl)acetamide (OR 1896)

4/2008Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment.
1/2007Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jaakko Puttonen Research Topics

Disease

2Heart Failure
04/2008 - 01/2007
1Alcoholic Liver Cirrhosis (Alcoholic Cirrhosis)
04/2008
1Renal Insufficiency (Renal Failure)
01/2007
1Chronic Kidney Failure (Chronic Renal Failure)
01/2007
1Parkinson Disease (Parkinson's Disease)
10/2002

Drug/Important Bio-Agent (IBA)

2N- (4- (4- methyl- 6- oxo- 1,4,5,6- tetrahydropyridazin- 3- yl)phenyl)acetamide (OR 1896)IBA
04/2008 - 01/2007
2Simendan (Levosimendan)IBA
04/2008 - 01/2007
1Vasodilator Agents (Vasodilators)IBA
04/2008
1CalciumIBA
01/2007
1CreatinineIBA
01/2007
1Pharmaceutical PreparationsIBA
01/2007
1Levodopa (L Dopa)FDA LinkGeneric
10/2002
1entacapone (Comtan)FDA Link
10/2002